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Abstract
Objective: To determine the prevalence of β thalassemia in Sindhi community of Wardha and evaluation of risk factors. 
To give genetic counseling to those diagnosed as carriers.
Study Design: Cross-sectional (prevalence study).
Setting: Sindhi community residing in and around Wardha.
Study Period: 18 months.
Materials and Methods: A total of 578 individuals belonging to Sindhi community residing in and around Wardha in 
India were selected by systemic randomization. Those who fulfilled the inclusion criteria and voluntarily gave consent 
were subject to Naked Eye Single Tube Rapid Osmotic Fragility Test (Nestroft). Those found positive by Nestroft were 
labeled carriers and advised to undergo Hemoglobin A2 (HbA2) quantification for confirmation of carrier status. Carriers 
thus identified were given genetic counseling.
Result: The mean age of study population was 15.06 years with a range of 3-28 years. The largest group consisted 
of those between 12 and 18 years. The prevalence of β thalassemia carrier state as diagnosed by Nestroft is 
36.36% (200/550) and incidence of carrier state by HbA2 quantification in the study population was 17.2% (95/550).
Conclusion: Prevalence of β thalassemia in the Sindhi community of Wardha is higher than in other studies and equal 
to the highest prevalent communities in India. Thus, we recommend that urgent measures to increase awareness and 
control the disease be taken.
Key words: Hemoglobin A2 quantification, naked eye single tube rapid osmotic fragility test, prevalence, Sindhi community, 
β thalassemia
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Introduction
Thalassemias are a heterogenous group of inherited 
hematological disorders characterized by defect in the rate 
of special globin chains. Thalassemia is considered the most 
common single gene disorder worldwide occurring with 
high frequency from Mediterranean basin through Middle 
East, Indian subcontinent, Burma and South East Asia, and 
Islands of Pacific.
Thalassemia is assigned α, β, γ, δ, and ε thalassemia depending 
on the chain whose synthesis is impaired. According to WHO 
data, there are 269 million carriers of thalassemia and 150 
million of β thalassemia alone out of which 40 million are in 
South East Asia. In India, thalassemia is the most common 
single gene disorder with approximately 30 million carrying 
the defective gene, with carrier frequency ranging from 
3% to 17%.[1‑3] β  thalassemia major is an inborn error of 
hemoglobin synthesis with clinical manifestations arising due 
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to severe anemia, ineffective erythropoiesis and in transfused 
patients iron overload. Clinical result in untreated patients is 
a catastrophic failure of growth and development, inanition, 
high output cardiac failure, susceptibility to infections, 
bony deformities, and early death without treatment. The 
average life of untreated β thalassemia major was less than 
4 years, <80% dying in the first 5 years. The main modality 
of treatment is regular blood transfusions every 2‑4 weekly 
coupled with iron chelation. With this treatment, a few 
lucky ones have reached 3rd or 4th decade. The only curative 
treatment currently available, in the form of bone marrow 
transplantation, is beyond the reach of all but a lucky 
few.[4] Cost of ideal treatment for one thalassemic child is 
Rs. 1,25,000/annum hence for 50,000 children will be Rs. 
620 crores. This staggering cost is beyond the reach of our 
country, India; moreover, this cost is expected to increase 
due to additional children being born. Transfusions alone cost 
20‑30% of the income of most families. The chronic nature 
of the disease and demanding treatment place significant 
financial, emotional, and social stress on the family.
In this scenario, prevention and control of thalassemia deserve 
a top priority. Experiences in Cyprus, Greece, and Italy show 
that this genetic disease can be efficiently controlled by public 
education, population screening, genetic counseling, and 
antenatal diagnosis. The incidence of thalassemia major by 
these simple measures has been reduced by 96% in Cyprus, 
62% in Italy, and 52% in Greece.[5‑7] Mass screening would 
involve huge outlay of resources and manpower; hence, 
targeted screening in the form of high‑risk screening of 
individuals at risk is a good option. Naked Eye Single Tube 
Rapid Osmotic Fragility Test (Nestroft) is a highly sensitive 
screening test with negative predictive value of approx 99%, 
sensitivity ranging from 86% to 99%, and specificity ranging 
from 66% to 100% in various studies.[8‑15]
Thalassemia is a widespread, highly prevalent disease 
not a disease of “just a few people.” Worldwide improved 
medical and health care has resulted in increased life 
expectancy. Globally, this translates in increased life 
expectancy. It is hence warranted that more attention be 
paid to screening and prevention The Sindhi community 
residing in and around Wardha accounts for most of the 
β thalassemia patients in the region. As the first step in 
disease prevention is identification of carriers, hence this 
study aims to determine prevalence of β thalassemia in 
this community, increase awareness and impart genetic 
counseling to reduce incidence of the disease in the 




This study was a cross‑sectional study (prevalence study).
Setting
This study was conducted in Sindhi population residing in 
and around Wardha, a high‑risk community for thalassemia 
major. Sindhis in Wardha are primarily a trading community 
comprising 1,004 heholds and a population of 5,500.
Inclusion criteria
Belonging to Sindhi community, residing in and around 
Wardha. Children, adolescents, unmarried adults, and 
married adults desiring more children.
Exclusion criteria
Community other than Sindhi, not residing in or around 
Wardha. Married individuals having desired number 
of children and thus not planning to have children in 
future (unlikely to benefit from screening) and known cases 
of thalassemia major.
Individuals were screened in three camps conducted during 
a period of 18 months.
Study population
Out of 3,500 individuals who fulfilled the inclusion criteria, 
every 6th individual was selected by systematic randomization. 
Out of the 578 individuals thus selected, Nestroft was 
performed on all. Those found positive by Nestroft were 
advised to undergo HbA2 quantification to confirm their 
carrier status. However, 28 individuals refused to undergo 
tests and hence have been excluded from the study.
Selection
Individuals to be screened were selected by systemic 
randomization among those who fulfilled the inclusion 
criteria and registered voluntarily for the camp and were 
enquired about marital status, sex, consanguinity, and family 
history. Consent was taken from parents of children and 
adolescents and individuals before inducting in the study.
Sensitizing the community
Attempts were made to sensitize the community regarding 
severity of the disease, nature of inheritance; how a carrier 
may be apparently normal. This was done by distributing 
information brochures in Hindi. Informative talks by 
eminent personalities who were masters on the subject 
were arranged before the camps. Posters were put up at 
camp sites and individual visits to household with the help 
of volunteers.
Screening
Screened individuals were subjected to Nestroft.
Methodology of naked eye single tube rapid osmotic 
fragility test
Stock solution in the form of 10% buffered saline with pH 7.4 
was prepared with NaCl 90 g, anhydrous Na2HPO4 13.65 g, 
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and NaH2PO4 2.43 g (can be stored in well‑stoppered bottle 
in refrigerator for 6 months). Working buffer was prepared 
fresh by putting 3.6 ml of stock solution for 100 ml buffer (by 
adding distilled water).
Collection of blood sample
Finger prick for Nestroft and 2 ml of venous sample for HbA2 
quantification. Blood collected for HbA2 quantification can 
be stored at 2‑6°C in dipotassium ethylenediaminetetraacetic 
acid (EDTA) bulb for up to 1 week; however, sample was 
sent to the laboratory the very same day and temperature 
of 2‑6°C maintained during transport.
Procedure and interpretation of naked eye single tube 
rapid osmotic fragility test
To 2 ml of working solution, 1 drop of blood was added 
and kept aside in room temperature for half an hour. It 
was observed half an hour later against a 1 mm line drawn 
on a white sheet. Control with distilled water was done. 
If clear line is visible, test is positive. Test was observed 
independently by three observers and even one positive 
was considered positive.[4,8,16,17]
Hemoglobin A2 quantification
Nestroft positive patients were advised for HbA2 
quantification. This was done by separating bands by 
cellulose acetate membrane electrophoresis. These bands 
were then eluted and HbA2 quantification done by 
spectrophotometric analysis of solution (optical density).[5]
Interpretation
Normal: 1.7‑3.5%, Minor: 3.5‑10%, Major: >10% (not of 
diagnostic significance).
Genetic counseling
Parents of thalassemia carriers were reassured regarding the 
innocuous nature of disease and explained about the need 
of avoiding marriage of their child to another thalassemia 
carrier. Married couples who were both carriers were told 
that in each pregnancy, they have 25% chance of having 
a normal child, 25% of thalassemia major, and 50% chance 
of thalassemia carrier. They were counseled regarding the 
option of prenatal diagnosis and of selective termination of 
affected fetuses if they so desire. All individuals attending 
camps were counseled regarding available treatment facilities 
and facilities for prenatal diagnosis of thalassemia major.
Methodology of statistical analysis
Data thus collected were used for estimating the prevalence 
of thalassemia in Sindhi community residing in and around 
Wardha. Fischer’s exact test was done to evaluate the 
risk factor using graphpad. The data were analyzed using 
EpiInfo6 software (developed by CDC, Atlanta USA 
courtesy Wikipedia) and Microsoft Excel and Stata program 
release 8.0.
Results
The study was a cross‑sectional study conducted in the 
Sindhi community residing in and around Wardha which 
is a high‑risk community for thalassemia. 550 individuals 
were screened in three camps.
Prevalence of β thalassemia carrier state in children 
and young adults of Sindhi community of Wardha
Total individuals selected were 578 out of which 28 
individuals refused to undergo tests and hence have been 
excluded from further calculations of prevalence. Prevalence 
based on (screening test) nestroft is 36.36%(200/550). 
Total individuals found to be β thalassemia trait by taking 
HbA2 3.5‑10 were 97/550. Hence, 17.2% of the population 
has thalassemia trait.
Table 1 shows the baseline characteristics of study population 
and profile of carriers.
The mean age of the study population was 15.06 years 
with a range of 3‑28 years. They were arbitrarily divided 
into three groups depending on difference in post‑test 
counseling. Among the carriers, 22.9% were  < 12 years, 
47.3% were 12‑18 years, and 29.8% were > 18 years (13.1% 
married and 16.7% unmarried). Among the carriers, 51.5% 
were males and 48.4% females. 11.8% of the population 
had a family history of thalassemia major. Family history 
of consanguineous marriage was found in 5.1% of the 
population. Various risk factors for thalassemia are evaluated 
in Table 2. Thalassemia carrier state was similar in married 
versus unmarried adults; hence, marital status is not a risk 
factor. Prevalence of thalassemia was similar in both sexes as 
inheritance is not sex linked. The prevalence of thalassemia 
in those with a family history of thalassemia (64.6%) was 
significantly higher than those without family history. It 
shows that the proportion of thalassemia carrier in those 
with and without a family history of consanguinity was 60% 
and 15.3%, respectively. Hence, consanguineous marriage 
Table 1: Baseline characteristics of study population
Total cases (%)
Age group
<12 years (126) (22.9)
12-18 years (260) (47.3)





Present (28) 28 (5.1)
Absent (522) 522 (94.9)
Family h/o thalass major
Present (65) 11.8
Absent (485) 88.2
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among high‑risk communities is a risk factor for thalassemia 
trait. The study shows that thalassemia carrier is an 
innocuous disease, usually asymptomatic; hence, screening 
is essential for diagnosis. Pallor visible on examination was 
also seen in just 2% of carriers.
Discussion
Birth of a thalassemic child places immense stress on 
the family as it is associated with regular hospital visits, 
expensive treatment, and painful procedures. Only 10‑15% 
of all thalassemic children born per year get optimal therapy 
in the form of regular blood transfusions and chelation. The 
only curative treatment currently relevant in India in the 
form of bone marrow transplant is beyond the reach of all 
but a lucky few. In this scenario, prevention and control 
of thalassemia deserve a top priority. This can be made 
possible by increasing awareness and screening individuals 
so that prevention is possible [Figure 1]. Mass screening 
would involve a huge outlay of resources and manpower; 
hence, targeted screening in the form of high‑risk screening 
of communities at risk, extended family screening, routine 
antenatal ANC screening, and screening as part of school 
health program are options available to us. High‑risk 
screening is a good option as it targets a population most 
likely to benefit from screening and also easy to motivate.
Figure 1: Approach to high risk screening for thalassemia
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It is estimated that about 1,00,000 children with 
transfusion‑dependent thalassemia are born worldwide 
annually, out of which 8,000‑10,000 are born in India. 
Cost of optimal treatment for 50,000 children will be 
Rs. 6.25‑10 billion and expected to rise by about Rs. 100 
crore every year due to additional children born every year. 
40% of 8,000 blood units collected in Red Cross Blood banks 
are taken up for transfusion of these children.[18] Carrier 
frequency ranges from 3% to 17%.[4,19] Sindhi community 
residing in and around Wardha is a high‑risk community 
for thalassemia and accounts for most of the thalassemic 
patients in the region. Prevalence of thalassemia in the 
Sindhi community residing in and around Wardha in this 
study ,using Nestroft is 36.36%. Gene frequency using HbA2 
quantification as the gold standard is 17.2%.
Result of studies on prevalence of β thalassemia trait in 
Sindhi communities are given in Table 3. Thalassemia, as was 
initially believed is clearly not restricted to the Mediterranean 
regions but also prevalent in Indian Subcontinent in different 
castes and communities like Gujaratis, Khoja, Bora, Sindhis, 
Punjabis, Baniyas and different religions such as Muslims, 
Jains, etc.[1] Large‑scale population surveys undertaken in 
India showed incidence of β thalassemia in Bengalis to be 
3.7%. Chaterjee et al.[20] and Sen et al.[21] found the incidence 
of β‑globin chain mutations up to 20% in tribals of Eastern 
India. Mathur et al.[22] found incidence to be 1.37% in Uttar 
Pradesh (immigrant population). Balgir et al.[23] found the 
prevalence of β thalassemia trait to be 18.2%, β thalassemia 
major 5.3%, and thalassemia intermedia 0.5% in Orissa. 
Ramot et al.[24] found an incidence of 16.6% in Kerala 
Jews. Verma[25] found thalassemia to contribute 8.8% of 
entire burden of genetic disorder in India and found that β 
thalassemia has a frequency of 1 in 2,700 births. In another 
study, incidence in Halai Lohanas was found to be 17.24%.[26]
The prevalence in this study is higher probably as there 
have been no attempts to screen individuals or prevent 
marriage between carriers, and marriage in the same closely 
knit community over the years have resulted in higher 
prevalence. All the previous studies have been conducted in 
urban areas with a greater degree of awareness, underlying 
the importance of urgent intervention in rural areas. Family 
history of thalassemia in 12% and history of consanguinity 
in 5% of screened population may have been responsible 
for higher prevalence.
Regarding risk factors, sex and marital status are not 
related to the inheritance of thalassemia as is well known 
and corroborated from the study. Consanguineous 
marriage among high‑risk groups is a significant risk factor 
understating the autosomal recessive nature of inheritance. 
Family history of thalassemia is also a significant risk factor 
for thalassemia due to genetic nature of the disease.
The following strategies are recommended for control of 
thalassemia in India
•  Sensitizing the community using newspapers, 
advertisements, TV, and mass media
Table 2: Parameters used for predicting thalassemia carrier state
Parameters Nestroft positive Significance HbA
2
>3.5% Significance
Marital status (>18 years) P value 0.34 not significant P value 0.55 not 
significantMarried (72) 36 13
Unmarried (92) 42 17




>3.5 P value is 1.000 
not significantMale (%) 107 (37.5) 49 (17.19)
Female (%) 93 (35.1) 46 (17.3)




>3.5 P value 0.0001
Present (%) 20 (71.4) 17 (60)
Absent (%) 179 (34.3) 80 (15.3)





Present (%) 49 (75.3) 42 (64.6)
Absent (%) 151 (31.1) 53 (10.9)
HbA=Hemoglobin A2, Nestroft=Naked eye single tube rapid osmotic fragility test
Table 3: Result of Prevalence studies in Sindhi Community
Community Region No tested Method Prevalence 
of gene %
Conducted by
Sindhi lohanas Bombay 134 HbA
2
 quantification 6-8 Bhatia H.M. et al.[18]
Sindhis Ulhasnagar 82 HbA
2
 quantification 12.4 Sukumaran P.K.[2]
Sindhis Gujarat and maharashtra 2525 HbA
2
 quantification 7.7 Manglani M. et al.[9]
Sindhis Wardha 550 HbA
2
 quantification 17.2 Present study
HbA2=Hemoglobin A2
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•  Screening high‑risk groups in the form of voluntary 
screening of high‑risk communities and extended family 
screening
•  Genetic counseling to those diagnosed as carriers: For 
parents of children <12 years counseling is aimed at first 
reassurance regarding the innocuous nature of the disease 
and prevention of marriage of their children to thalassemia 
traits to prevent birth of thalassemia major children. 
12‑18 years children and those >18 years but married along 
with parents are given information regarding inheritance 
of thalassemia and the need to prevent marriage to traits. 
For carriers aged >18 years and married to a thalassemic 
carrier, the need to screen their unborn child is explained. 
Options available (for diagnosing thalassemia) widely by 
amniocentesis, cordocentesis, and isolation of fetal cells 
from maternal blood should be explained with associated 
adverse effects. If a fetus is thus diagnosed to be thalassemia 
major, option of termination of pregnancy is given. For 
those couples for whom termination of pregnancy is 
not acceptable, pre‑implantation diagnosis following 
In vitro Fertilization (IVF) is made using Polymerase 
Chain Reaction, Fluorescent (PCR), Fluorescent in situ 
Hybridization (FISH).
Limitations
Individuals who were married and had completed their 
family and older individuals were excluded from the study. 
This could affect the prevalence; however, this was done 
as these people were unlikely to benefit from the screening. 
28 individuals screened by Nestroft were lost to follow‑up 
due to economic reasons.
Conclusion
More efforts are needed to increase awareness of high‑risk 
communities like Sindhis regarding β thalassemia before 
dreams of disease control can be fulfilled.
One of the most cost‑effective and simple methods of decreasing 
thalassemia is by high‑risk community screening and genetic 
counseling. Prevalence of β thalassemia in Sindhis residing in 
and around Wardha is 36.6% by Nestroft and prevalence of the 
defective gene by HbA2 quantification is 17.2% which is higher 
than Sindhis in Ulhasnagar[2] and Sindhi Lohanas[18] and equal 
to the highest prevalence in communities like Cutchi Lohanas, 
Cutchi Bhanusalis, and Halai Lohanas.[5]
Thus, we recommend that urgent measures be taken to 
increase the awareness of high‑risk communities about the 
disease, inheritance, and prevention. When one considers 
the repeated yearly expenses of bringing up a child with 
thalassemia, preventing thalassemic births by diagnosing 
and counseling of β thalassemia traits seems to be the more 
easier and effective solution.
References
1. Chouhan DM Chouhan V. Epidemiology: Symposium on thalssaemia. Indian J 
Hematol Blood Transf 1992;10:1‑20
2. Sukumaran PK, Master HR. The distribution of abnormal haemoglobins in 
the Indian population. In: Proceedings of the First Conference of the Indian 
Society of Human Genetics. Human Population Genetics in India. Mumbai: 
Brient Longman; 1973. p. 91‑111.
3. Lokeshwar MR. Late Hony. Surg. Cmde. Dr. Shantilal C. Sheth oration 
presentation during PEDICON 2006, Delhi, January 6th, 2006. Progress in the 
management of thalassemia. Indian Pediatr 2006;43:503‑6.
4. Panigrahi I, Ahmed RP, Kannan M, Kabra M, Deka D, Saxena R. Cord blood 
analysis for prenatal diagnosis of thalassemia major and hemophilia A. Indian 
Pediatr 2005;42:577‑81.
5. Angastiniotis M, Modell B, Englezos P, Boulyjenkov V. Prevention and control 
of haemoglobinopathies. Bull World Health Organ 1995;73:375‑86.
6. Angastiniotis MA, Hadjiminas MG. Prevention of thalassaemia in Cyprus. Lancet 
1981;1:369‑71.
7. Angastiniotis M, Kyriakidou S, Hadjiminas MG. How thalassemia was controlled 
in Cyprus.  World Health Forum 1986;7:291‑7.
8. Maheshwari M, Arora S, Kabra M, Menon PS. Carrier screening and prenatal 
diagnosis of beta‑thalassemia. Indian Pediatr 1999;36:1119‑25.
9. Manglani M, Lokeshwar MR, Vani VG, Bhatia N, Mhaskar V. ‘NESTROFT’: An 
effective screening test for beta thalassemia trait. Indian Pediatr 
1997;34:702‑7.
10. Mehta BC. NESTROFT: A screening test for beta thalassemia trait. Indian J 
Med Sci 2002;56:537‑45.
11. Mehta J, Singhal S, Mehta G, Mehta BC. Megaloblastosis: A cause of false 
negative NESTROFT. J Assoc Physicians India 1991;39:364‑5.
12. Raghavan K, Lokeshwar MR, Birewar N, Nigam V, Manglani MV, Raju NB. 
Evaluation of naked eye single tube red cell osmotic fragility test in detecting 
beta‑thalassemia trait. Indian Pediatr 1991;28:469‑72.
13. Thomas S, Srivastava A, Jeyaseelan L, Dennison D, Chandy M. NESTROFT 
as a screening test for the detection of thalassaemia and common 
haemoglobinopathies: An evaluation against a high performance liquid 
chromatographic method. Indian J Med Res 1996;104:194‑7.
14. Bobhate SK, Gaikwad ST, Bhaledrao T. NESTROFF as a screening 
test for detection of Beta‑thalassemia trait. Indian J Pathol Microbiol 
2002;45:265‑7.
15. Gomber S, Sanjeev, Madan N. Validity of Nestroft in screening and diagnosis 
of beta‑thalassemia trait. J Trop Pediatr 1997;43:363‑6.
16. Verma IC, Choudhry VP, Jain PK. Prevention of thalassemia: A necessity in 
India. Indian J Pediatr 1992;59:649‑54.
17. Hereditary anaemias: Genetic basis, clinical features, diagnosis, and treatment. 
WHO working group. Bull World Health Organ 1982;60:643‑60.
18. Bhatia HM, Shanbagh SR, Baxi AJ, Bapat JP, Sharma RS. Genetic studies among 
the endogamous groups of Lohanas of North and West India. Hum Hered 
1976;26:298‑305.
19. Lo L, Singer ST. Thalassemia: Current approach to an old disease. Pediatr 
Clin North Am 2002;49:1165‑91.
20. Chatterjea JB, Saha AK, Ray RN, Ghosh SK. Hemoglobin E‑thalassemia disease. 
Indian J Med Sci 1957;11:553‑64.
21. Sen R, Chakrabarti S, Sengupta B, De M, Haldar A, Poddar S, et al. Alpha‑thalassemia 
among tribal populations of Eastern India. Hemoglobin 2005;29:277‑80.
22. Mathur KS, Mehrotra TN, Dayal RS, Yadav SN. Incidence of HbE and 
thalassaemia in Uttar Pradesh. J Indian Med Assoc 1962;39:172‑7.
23. Balgir RS. Spectrum of hemoglobinopathies in the state of Orissa, India: A ten 
years cohort study. J Assoc Physicians India 2005;53:1021‑6.
24. Ramot B, Abrahamov A, Frayer Z, Gafni D. The incidence and types of 
thalassaemia‑trait carriers in Israel. Br J Haematol 1964;10:155‑8.
25. Verma IC. Burden of genetic disorders in India. Indian J Pediatr 2000;67:893‑8.
26. Bhatia HM. Genetic parameters: Biologic and epidemiology significance. Indian 
J Med Sci 1987;41:203‑7.
How to cite this article: Rakholia R, Chaturvedi P. Prevalence of β 
thalassemia carrier state in Sindhi community of Wardha and evaluation of 
risk factors for β thalassemia trait. Niger J Clin Pract 2013;16:375-80.Source 
of Support: Nil, Conflict of Interest: None declared.
